Spot­light­ing sub­group analy­sis, Ther­a­vance tries to carve out 'nar­row, but crit­i­cal­ly im­por­tan­t' mar­ket for failed drug

When Ther­a­vance Bio­phar­ma re­vealed last Sep­tem­ber that its first Phase III tri­al for am­prelox­e­tine had end­ed in fail­ure, it de­mot­ed the drug from lead sta­tus and laid off 75% of its work­force to stay afloat. But CEO Rick Win­ning­ham vowed to “con­tin­ue to an­a­lyze the da­ta to bet­ter un­der­stand the find­ings.”

As it re­ports a sec­ond flop for the same can­di­date, it’s stick­ing to the same ap­proach to find a sil­ver lin­ing in the da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER